Contract Pharmaceutical Manufacturing Market to Grow at Highest Pace owing to Increasing Demand for Generic Drugs

The contract pharmaceutical manufacturing market involves manufacturing drugs or pharmaceutical products on a contract basis. Many pharmaceutical companies outsource their manufacturing needs to contract manufacturing organizations to focus on drug development and marketing activities. Contract manufacturing helps pharmaceutical firms reduce production costs and meet increased demand without major investments or recurring costs associated with in-house manufacturing. Services offered by CMOs include active pharmaceutical ingredient (API) and raw material sourcing, product development and formulation, clinical trial manufacturing, commercial manufacturing, packaging, and logistics.

Global contract pharmaceutical manufacturing market is estimated to be valued at USD 232.28 Bn in 2025 and is expected to reach USD 450.07 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 9.9% from 2025 to 2032.

Key Takeaways

Key players operating in the contract pharmaceutical manufacturing market are Lonza Group, Boehringer Ingelheim GmbH, Genpact Limited, Accenture plc, Quintiles Transnational Corporation, Baxter, Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma, Pfizer, Inc., The Almac Group, Teva Pharmaceutical Industries Ltd., Piramal Enterprises Ltd., Covance, Inc., Catalent, Inc., Abbvie, Inc., and Celltrion.

Contract Pharmaceutical Manufacturing Market Demand is driven by the growing demand for generics and biologics, increased outsourcing, and the patent cliff of major drug molecules, boosting the generic drugs market.

Emerging technologies such as 3D printing, continuous manufacturing, and advanced process analytical technology (PAT) help improve manufacturing efficiency and flexibility for CMOs to better address client needs.

Market Trends

Growing demand in emerging markets - Emerging countries such as India, China, Brazil, Mexico are showing increased demand for affordable medicines. This is boosting investments by CMOs in these regions to expand capacities and capabilities.

Increased focus on specialized services - CMOs are adding specialized capabilities and expertise around controlled substances, oncology products, and biosimilars to assist pharmaceutical companies and gain greater market share.

Market Opportunities

Cell and gene therapy manufacturing - Outsourcing of cell and gene therapy manufacturing is expected to grow significantly owing to the technical complexity and investments required for specialized facilities and equipment.

Rapid response manufacturing for clinical trials - CMOs are developing capabilities for small batch, rapid response manufacturing to address the demand for expedited production of treatments during clinical trials of innovative drug candidates.

Impact of COVID-19 on Contract Pharmaceutical Manufacturing Market

The COVID-19 pandemic has significantly impacted the growth of the contract pharmaceutical manufacturing market. During the initial lockdown period, drug manufacturing plants faced operational challenges due to limited workforce and disruptions in supply chains. This led to delays in contract pharmaceutical production activities. However, the demand for vaccines and drugs surged rapidly as the virus spread worldwide. Many pharmaceutical companies lacking in-house manufacturing facilities signed new contracts with Contract Manufacturing Organizations (CMOs) to meet this excess demand. In the post-COVID period as well, the pandemic is expected to fuel the market growth due to continuation of vaccine development programs and increased investments in healthcare infrastructure by governments worldwide.

While short term opertaional challenges were faced, many CMOs adapted well by developing new safety protocols, recruiting more workforce and streamlining material supply chains on a priority basis. Most large CMOs enhanced their production capacities through facility expansions to capitalize on emerging growth opportunities. The pandemic also accelerated the ongoing trend of outsourcing drug manufacturing services by big pharmaceutical firms. It highlighted the strategic importance of using flexible external manufacturing networks to ensure supply security. In future, greater emphasis is likely to be placed on pandemic preparedness and development of therapies for treating infectious diseases which will further benefit the contract pharmaceutical manufacturing industry.

Geographical Regions

In terms of value, North America accounted for the largest share of the global contract pharmaceutical manufacturing market in 2020. This was majorly attributed to presence of many leading global pharmaceutical companies and healthcare tech firms based out of US and Canada. These organizations outsource a large volume of their drug production requirements to well established domestic CMOs. Going forward, increased government funding for Covid vaccine development and manufacturing will continue to drive high market demand from the region.

Fastest Growing Regions

The Asia Pacific region is poised to become the fastest growing market for contract pharmaceutical manufacturing during the forecast period. This is due to increasing investments by international pharmaceutical giants to expand outsourcing operations to low cost Asian countries like India and China which offer skilled workforce at competitive prices. Rising health awareness and investments by regional governments in building specialized manufacturing infrastructure are also supporting the regional market growth. Countries like South Korea are also emerging as new prominent hubs for contract biologics manufacturing.

Get More Insights - Contract Pharmaceutical Manufacturing Market

Get This Report in Japanese Language -契約医薬品製造市場

Get This Report in Korean Language - 계약 제약 제조 시장

About Author:

Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.

(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)